- Investing Ideas
- South Korean Pharmaceuticals & Biotech Undervalued based on future growth
South Korean Pharmaceuticals & Biotech Undervalued based on future growth
Results
5
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
5 companies
Hugel
Market Cap: ₩2.7t
Develops and manufactures biopharmaceuticals in South Korea and internationally.
A145020
₩248,500.00
7D
-7.1%
1Y
-26.2%
Oscotec
Market Cap: ₩1.6t
Operates as a biotechnology company, engages in the drug development, functional materials and related products, and dental bone graft material businesses.
A039200
₩40,550.00
7D
-4.0%
1Y
40.8%
Daihan PharmaceuticalLtd
Market Cap: ₩157.0b
Engages in the manufacture and sale of therapeutic drugs in South Korea.
A023910
₩26,350.00
7D
-5.7%
1Y
-7.5%
Macrogen
Market Cap: ₩140.8b
Provides precision medicine and bio-engineering healthcare services in Korea and internationally.
A038290
₩12,470.00
7D
-11.6%
1Y
-20.9%
DreamCIS
Market Cap: ₩121.8b
Operates as a clinical research organization in South Korea.
A223250
₩4,620.00
7D
-19.7%
1Y
53.0%